Cargando…
HBV Pre-S1-Derived Myristoylated Peptide (Myr47): Identification of the Inhibitory Activity on the Cellular Uptake of Lipid Nanoparticles
The Myr47 lipopeptide, consisting of hepatitis B virus (HBV) pre-S1 domain (myristoylated 2–48 peptide), is an effective commercialized anti-HBV drug that prevents the interaction of HBV with sodium taurocholate cotransporting polypeptide (NTCP) on human hepatocytes, an activity which requires both...
Autores principales: | Nanahara, Masaya, Chang, Ya-Ting, Somiya, Masaharu, Kuroda, Shun’ichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157113/ https://www.ncbi.nlm.nih.gov/pubmed/34067884 http://dx.doi.org/10.3390/v13050929 |
Ejemplares similares
-
Reporter gene assay for membrane fusion of extracellular vesicles
por: Somiya, Masaharu, et al.
Publicado: (2021) -
Elucidation of the early infection machinery of hepatitis B virus by using bio-nanocapsule
por: Liu, Qiushi, et al.
Publicado: (2016) -
Current Progress of Virus-mimicking Nanocarriers for Drug Delivery
por: Somiya, Masaharu, et al.
Publicado: (2017) -
Binding of Hepatitis B Virus Pre-S1 Domain-Derived Synthetic Myristoylated Peptide to Scavenger Receptor Class B Type 1 with Differential Properties from Sodium Taurocholate Cotransporting Polypeptide
por: Hinuma, Shuji, et al.
Publicado: (2022) -
Nano-visualization of oriented-immobilized IgGs on immunosensors by high-speed atomic force microscopy
por: Iijima, Masumi, et al.
Publicado: (2012)